Abstract 216P
Background
A previous pan-cancer single-cell study on the tumor microenvironment (TME), particularly tumor-infiltrating lymphocytes (TILs), highlighted both the heterogeneity and dynamics of various T cell subtypes. However, the spatial heterogeneity of TILs in breast cancer has not been extensively studied. We aimed to investigate the spatial heterogeneity of the TME using spatial transcriptomics.
Methods
We retrospectively collected FFPE samples from five breast cancer cases (2 triple-negative breast cancer [TNBC] with high TILs, 2 TNBC with low TILs, 1 hormone receptor-positive[HR+] breast cancer with TIL high TILs) and performed the Visium Spatial Gene Expression method (10x Genomics). Subsequently, using public TILs single-cell data from a pan-cancer study, we predicted and annotated cell types in each Visium spot (single cell deconvolution). We studied the distribution of T cell subtypes across three layers at 3mm intervals from the most peripheral to the central direction of the tumor.
Results
The distribution of 24 CD4+ subtypes and 17 CD8+ subtypes was examined. In all five cases, the CD8.c.12.Tex.CXCL13 subtype showed a statistically significant increase in cell numbers at the tumor center compared to the periphery. The CD4.c20.Treg.TNFRSF9 subtype displayed a similar trend, with higher cell counts in the tumor center and lower counts in the periphery. Conversely, the CD8.c10.Trm.ZNF683 subtype, a key subtype in the previous pan-cancer study, exhibited varying distribution patterns between cases.
Conclusions
TILs in breast cancer consist of diverse subtypes. Numerical heterogeneity was observed among T cell subtypes, along with spatial heterogeneity between the tumor’s central and peripheral regions. Furthermore, heterogeneity was evident between individual tumors. However, some consistent distribution patterns, such as the CD8.c.12.Tex.CXCL13 population, were also observed across cases. Further studies are needed to determine the clinical significance of this spatial heterogeneity.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session